Connect
← Return to John Hopkins Webinar on transplant recipients and vaccines
Discussion
John Hopkins Webinar on transplant recipients and vaccines
Transplants | Last Active: Jan 13, 2022 | Replies (141)Comment receiving replies
Hi everyone! Following the COVID vaccine conversation with TX folks has been interesting. After watching the JH webinars, I am content to wait for my doctors to release info that addresses our needs and my particular needs. That said, when we discuss T and B cells it's difficult. Those are the exact cells that our immuno-suppressant drugs affect. Our Tacro, Sirolimus, CellCept, etc. reduce the response from the T and B cells in order to avoid the opportunity for rejection of our heart, kidney, liver or other organ. So when we talk about relying on these cells to help us with COVID, I don't think it's scientifically reasonable to expect that. Does anyone know more about this? I would be glad to be mistaken! 🙂
Replies to "Hi everyone! Following the COVID vaccine conversation with TX folks has been interesting. After watching the..."
Connect
I’m not a medical professional, but I have done a lot of reading about Tacrolimus and Mycophenolate, how they’re metabolized and their functions in our bodies. And, yes, Tacrolimus is a calcineurin inhibitor, like Cyclosporine, designed to block production of T cells. Mycophenolate is designed to inhibit both T cell and B cell production.
I’d assume this is one of the reasons we’re required to get all of our vaccinations, such as shingles, tetanus, etc. prior to transplant so that we’ll at least build some antibodies to these viruses.